Strategic partnerships Kepley BioSystems operates from GURP in collaboration with JSNN, a joint venture between NCA&T and UNCG. This indicates potential for university-affiliated research collaborations, grant opportunities, and early-access pilots for academic medical centers or hospitals seeking innovative diagnostic tools.

Diagnostics focus The company developed a rapid and affordable blood screening tool for early sepsis detection, suggesting a strong value proposition in critical care settings. Sales opportunities exist with hospitals, urgent care networks, and blood screening providers seeking cost-effective, fast diagnostics.

Advisory growth Appointment of a new advisory board member signals strategic governance and industry guidance. Leverage this network to open introductions to biotech investors, healthcare thought leaders, and potential distribution partners.

Growth readiness Revenue range ($1M–$10M) and recent funding indicate a startup scale-up phase with appetite for strategic partnerships, pilot programs, and co-development deals to accelerate market entry and validation in clinical settings.

Emerging markets Operating in biotech with a scalable diagnostic tool positions KBI to explore opportunities in global health markets, regulatory environments, and academic hospital systems seeking rapid screening solutions that reduce sepsis-related morbidity and cost.